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Background. Contemporary antiretroviral therapies (ART) and management strategies have diminished both human immuno-
deficiency virus (HIV) treatment failure and the acquired resistance to drugs in resource-rich regions, but transmission of drug-re-
sistant viruses has not similarly decreased. In low- and middle-income regions, ART roll-out has improved outcomes, but has 
resulted in increasing acquired and transmitted resistances. Our objective was to review resistance to ART drugs and methods to 
detect it, and to provide updated recommendations for testing and monitoring for drug resistance in HIV-infected individuals.
Methods. A volunteer panel of experts appointed by the International Antiviral (formerly AIDS) Society–USA reviewed rele-
vant peer-reviewed data that were published or presented at scientific conferences. Recommendations were rated according to the 
strength of the recommendation and quality of the evidence, and reached by full panel consensus.
Results. Resistance testing remains a cornerstone of ART. It is recommended in newly-diagnosed individuals and in patients in 
whom ART has failed. Testing for transmitted integrase strand-transfer inhibitor resistance is currently not recommended, but this 
may change as more resistance emerges with widespread use. Sanger-based and next-generation sequencing approaches are each 
suited for genotypic testing. Testing for minority variants harboring drug resistance may only be considered if treatments depend 
on a first-generation nonnucleoside analogue reverse transcriptase inhibitor. Different HIV-1 subtypes do not need special consid-
erations regarding resistance testing.
Conclusions. Testing for HIV drug resistance in drug-naive individuals and in patients in whom antiretroviral drugs are failing, 
and the appreciation of the role of testing, are crucial to the prevention and management of failure of ART.
Keywords. HIV; antiretroviral therapy; drug resistance; therapeutic failure; resource-rich; low and middle income countries; 
HIV-1 subtype; genotypic drug resistance; sanger sequencing; next generation sequencing.
 Human immunodeficiency virus (HIV) drug resistance is an 
important contributor to failure of antiretroviral therapies 
(ART). In resource-rich regions, acquired HIV drug resistance as 
a result of treatment failure has diminished with the availability 
of better drugs and better monitoring for treatment failure and 
drug resistant viruses [1]. Transmission of drug-resistant virus, 
however, persists at prevalences of around 10% in resource-rich 
countries. The rollout of ART in low- and middle-income coun-
tries (LMIC) reduced morbidity and mortality [2], but over the 
last few years prevalences of 10% or higher of transmitted drug 
resistance (TDR) have been reached in some countries [3–7].
This report [8] examines recent information regarding 
HIV drug resistance in resource-rich and LMIC, and provides 
updated recommendations [8, 9]. Drug-resistant mutations 
(DRMs) that impact treatment responses are updated regularly 
[9]. Implementation of next-generation sequencing methods is 
increasing and has changed approaches to drug resistance testing. 
These new approaches, and the insights they provide (eg, minority 
drug-resistant variants), are also addressed. Table  1 provides a 
summary of definitions of terms relevant for HIV drug resistance.
EPIDEMIOLOGY, ORIGIN, AND EFFECT OF 
TRANSMITTED DRUG RESISTANCE
Prevalence of Transmitted Drug Resistance in Resource-rich Countries
Recommendations are provided in Appendix Box 1. TDR has 
been observed in virtually all countries where drug-resistance 
testing has been performed [3]. Frequencies vary substantially 
over time and by country. The prevalence of TDR is high-
est for nucleoside analogue reverse transcriptase inhibitors 
(nRTIs) and nonnucleoside analogue reverse transcriptase 
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inhibitors (NNRTIs); is lower for protease inhibitors (PIs); and, 
so far, is rare for integrase strand transfer inhibitors (InSTIs). 
Frequencies may vary by location and time of testing. Table 2 
summarizes the prevalence of TDR in some recent studies in 
seroconverter cohorts or in drug-naive individuals.
The prevalence of TDR ranged from 6.6% to 11% and time 
trends seem to be rather stable, except in the United Kingdom, 
where TDR prevalence peaked in 2002 at 14% and dropped to 8% 
to 9% in 2009 [18, 19] and to 6.6% in 2013 [12]. In the Swiss HIV 
Cohort Study, the yearly TDR prevalence in recently  infected 
patients fluctuated between 2.2% and 15.5% from 2000 to 2013, 
attributed in part to the introduction of new drugs (eg, boosted 
PIs in 2000 and InSTIs in 2008), after which substantial tran-
sient declines occurred [20]. Data on the transmission of InSTI 
resistances are scant. The larger studies, to date from the Swiss 
HIV Cohort Study and the United Kingdom, did not find any 
transmitted major InSTI DRMs since the class was introduced in 
2007, despite the fact that thousands of patients are being treated 
with these drugs [12, 16, 17]. Anecdotal cases, however, have 
been reported [21, 22]. Thus, as seen for all drugs used at high 
frequency, InSTI TDR likely will increase over time.
Prevalence of Transmitted or Pretreatment Drug Resistance in Low- and 
Middle-income Countries
With expanding use of ART in LMIC, acquired and transmitted 
drug resistance have increased [3–7]. It is increasingly recog-
nized that a considerable proportion of detected DRMs in indi-
viduals in LMIC, previously assumed to be ART-naive, resulted 
from undisclosed exposure to earlier ART, rather than TDR 
[23]. Thus in LMIC, pretreatment drug resistance (PDR) data 
are more feasible to collect than TDR data, and remain import-
ant for treatment decisions.
Table 3 summarizes selected recent studies of PDR in LMIC. 
Surveillance conducted by the World Health Organization 
(WHO) between 2015 and 2016 in 11 countries from Africa, 
middle/south America, and Asia found that Uganda, Namibia, 
Table 1. Definitions of Terms Used in the Field of HIV Drug Resistance Testing
Term Definition
Drug-resistance mutations Specific mutations in the HIV-genome that are associated with a reduced in vitro and in vivo activity of antiretroviral 
drugs. DRMs are drug-class specific and generally emerge in the gene, which is targeted by the specific antiretro-
viral drug.
Acquired drug resistance DRMs that are selected during antiretroviral therapy, which can happen when viral replication is not fully suppressed 
in the presence of drug.
Transmitted drug resistance DRMs that are transmitted by (1) patients with acquired drug resistance or, (2) drug-naive patients who were infected 
with a resistant HIV strain.
Pretreatment drug resistance All DRMs in patients before starting a treatment. TDRs, as well as DRMs from exposure to earlier ART, are included. 
Previous ART exposure, in particular in resource-limited settings, is often not disclosed; thus, TDR cannot reliably 
be determined in some settings.
HIV drug resistance by genotyping Genotyping identifies DRMs in the HIV genome (that are associated with reduced activity of antiretroviral drugs).
HIV drug resistance by phenotyping Phenotyping for drug resistance assesses the ability of a virus to grow in different concentrations of ARVs. Such re-
sistance characterizes the reduced activity of ARVs to inhibit growth of a virus in vitro.
Viral tropism Viral tropism is defined as the ability of HIV to selectively attach to a particular coreceptor on the surface of a host 
CD4 T-cell. The virus can attach either to the CCR5 coreceptor (R5-tropic), to the CXCR4 coreceptor (X4-tropic), or 
both (dual-tropic).
HIV-1 pol The HIV-1 polymerase is a gene that encodes for viral structural proteins, namely the viral enzymes protease, reverse 
transcriptase and RNase H, and integrase.
HIV-1 env The HIV-1 envelope gene encodes for the glycoprotein 160 protein, which is cleaved into gp120 and gp41. Those gly-
coprotein components mediate binding and entry into the target cell.
HIV-1 gag The HIV-1 gag, or group-specific antigen, encodes for a number of structural proteins relevant for the viral structure 
(matrix protein, p17; capsid protein, p24; spacer peptide 1, p2; nucleocapsid protein, p7; spacer peptide 2, p1) and 
p6 protein.
Sanger sequencing It has been used as the sequencing method of choice for commercially-available genotypic resistance testing. It is a 
DNA sequencing method used following reverse transcription of the viral ribonucleic acid genome, and is based on 
the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA repli-
cation. It requires a single-stranded DNA template, a DNA primer, a DNA polymerase, normal deoxynucleosidetri-
phosphates, and modified di-deoxynucleotidetriphosphates, the latter of which terminate DNA strand elongation. 
Today, mostly Dye-terminator sequencing is used. Each of the 4 dideoxynucleotide chain terminators are labelled 
with fluorescent dyes, each of which emits light at different wavelengths.
Next-generation sequencing These newer technologies most likely will replace Sanger sequencing–based resistance testing within the next few 
years in research and commercial labs. Next-generation sequencing refers to high-throughput DNA sequencing 
technologies. Millions of DNA strands can be sequenced in parallel, yielding substantially more throughput and 
minimizing the need for the fragment-cloning methods that are often used in Sanger sequencing of genomes.
Point mutation assays These assays are designed to detect predefined, known DRMs. They are primarily based on hybridization techniques, 
are relatively inexpensive, and only need simple laboratory equipment.
Home brew assays These assays (eg, genotypic resistance testing assays) are developed by research groups or diagnostic labs and are 
not commercially available.
Abbreviations: ART, antiretroviral therapy; ARV; antiretroviral drugs; DRM, drug resistance mutation; gp, glycoprotein; HIV, human immunodeficiency virus; TDR, transmitted drug resistance.
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Table 2. Summary of Selected Prevalence Studies of TDR Mutations in Resource-rich Settings
Study Name and Citation Country/Region Sample Size
Drug-naive Population
(Years Studied)
Prevalence of TDR Against Any Respectively Specific 
Drug Classes [No. (%)]
Any NNRTI nRTI PI InSTI
SPREAD Program [10] Europe 4140 Chronically infecteda,b 
(2008–2010)
344 (8.3) 120 (2.9)% 186 (4.5) 83 (2) NR
Robert Koch Institute [11] Germany 809 Recently infected 
(2013–2014)
87 (10.8)% 21 (2.6) 37 (4.6) 24 (3) NR
UK-CHIC [12] United Kingdom 3 527  
101 for InSTI 
testing
Chronicallya infected 
(2013)
233 (6.6) 116 (3.3) 124 (3.5) 60 (1.7) 0 (0)
ANRS PRIMO study [13] France 1318 Recently infected 
(2007–2012)
154 (11.7) 51 (3.9) 69 (5.2) 33 (2.5) NR
START Trial [14] Europe/United States/
Australia
1869c,d Chronicallya infected 
(2009–2013)
188 (10.1) 85 (4.5) 75 (4) 52 (2.8) NR
CASCADE [15] Europe (95%), Canada (1%), 
Australia 1%), sub-Saharan 
Africa (3%)
4717 Recently infected 
(1996–2012)
515 (11) 185 (3.9) 280 (5.9) 144 (3.1) NR
SHCS [16] Switzerland 1316 Chronicallya infected 
(2008–2014)
NR NR NR NR 0 (0)
Stekler et al., 2015 [17] United States (Seattle) 82 Chronicallya infected 
(2007–2012)
NR NR NR NR 0 (0)
Abbreviations: ANRS PRIMO, French National Agency for Research on AIDS; CASCADE, concerted action on Seroconversion to AIDS and death in Europe; InSTI, integrase strand transfer 
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NR, not reported; nRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SHCS, the Swiss HIV cohort study; 
SPREAD, strategy to control SPREAD of HIV drug resistance; START, strategic timing of antiretroviral treatment; TDR, transmitted drug resistance; UK-CHIC, The UK collaborative HIV cohort.
aDuration of infection was not known.
b13% of patients were recently infected.
cPretreatment resistance tests were available for 41.5% of all patients enrolled. Resistance tests were from Europe (69%), the United States (21%), Australia (5%), Asia (4%), and South 
America (1%).
dEnrollment for START was conducted on all continents.
Table 3. Summary of Selected Prevalence Studies of Pretreatment Drug Resistance in Resource-limited Settings
Study Name and 
Citation Country/Region Sample Size
Drug-naive Population
(Years Studied)
Prevalence of PDR Against Any  
Respectively Specific Drug Classesa 
Any NNRTI nRTI PI InSTI
WHO [23] Cameroon 321 Chronic (2015–2016) 24 (8.3) 23 (8.1) 5 (2.4) 1 (0.2) NR
WHO [23] Namibia 383 Chronic (2015–2016) 56 (14.6) 52 (13.8) 6 (1.6) 2 (0.5) NR
WHO [23] Uganda 342 Chronic (2016) 48 (17.4) 43 (15.4) 11 (5.1) 2 (1.0) NR
WHO [23] Zimbabwe 353 Chronic (2015–2016) 34 (10.9) 34 (10.9) 3 (0.8) 0 (0) NR
WHO [23] Guatemala 241 Chronic (2016) 34 (15.1) 29 (13.2) 9 (3.2) 2 (0.6) NR
WHO [23] Mexico 260 Chronic (2015–2016) 34 (13.5) 22 (9.2) 14 (5.5) 7 (2.6) NR
WHO [23] Nicaragua 171 Chronic (2015–2016) 40 (23.4) 33 (19.3) 18 (10.5) 0 (0) NR
WHO [23] Argentina 294 Chronic (2014–2016) 41 (13.8) 33 (10.9) 10 (3.7) 6 (1.9) NR
WHO [23] Brazil 1391 Chronic (2013–2016) 137 (9.8) 94 (6.8) 50 (3.6) 13 (0.9) NR
WHO [23] Colombia 192 Chronic (2016) 19 (9.9) 12 (6.3) 7 (3.6) 0 (0) NR
WHO [23] Myanmar 327 Chronic (2016) 21 (5.4) 16 (3.9) 5 (1.4) 1 (0.2) NR
Metanalysis,
Gupta et al. [5]
South Africa 11 855 Chronic (estimates  
for 2016)
11% [7.5–15.9] 10.7%b [8.4–13.7] 2.2b [1.2–3.8] NR NR
Metanalysis,
Gupta et al. [5]
Eastern Africa 7169 Chronic (estimates  
for 2016)
10.1% [5.1–19.4] 10.1%b [8.2–12.4] 3.2%b [3.3–8.5] NR NR
Metanalysis,  
Gupta et al. [5]
Western and Central Africa 4924 Chronic (estimates  
for 2016)
7.2% [2.9–16.5] 5.3%b [3.3–8.5] 3.7%b [2.0–6.5] NR NR
Metanalysis,  
Gupta et al. [5]
Latin America and Caribbean 16 008 Chronic (estimates  
for 2016)
9.4% [6.2–12.4] 8.8%b [6.2–12.4] 4.1%b [2.5–6.5] NR NR
Metanalysis,  
Gupta et al. [5]
Asia 16 088 Chronic (estimates  
for 2016)
3.2% [1.8–5.6] 4%b [2.1–6.7] 1.5b [0.5–3.5] NR NR
Abbreviations: InSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NR, not reported; nRTI, nucleoside reverse transcriptase inhibitor; PDR, pre-
treatment drug resistance; PI, protease inhibitor; WHO, World Health Organization.
aValues are provided as either No. (%) or % [confidence interval].
bData published in supplementary appendix on page 18 of Gupta et al. [5].
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Zimbabwe, Nicaragua, Guatemala, and Argentina were above 
the critically-defined NNRTI TDR/PDR threshold of 10% 
[23]. A meta-analysis of 56 044 adults with HIV infection from 
64 LMIC estimated annual increases of the odds of PDR for 
NNRTIs of 23% (95% confidence interval [CI], 16–29) in south-
ern Africa, 17% (95% CI, 5–30) in eastern Africa, 17% (95% 
CI, 6–29) in western and central Africa, 11% (95% CI, 5–18) 
in Latin America and the Caribbean, and 11% (95% CI, 2–20) 
in Asia [5]. Estimated absolute increases in prevalence of PDR 
between 2015 and 2016 ranged from 0.3% in Asia to 1.8% in 
southern Africa.
A meta-analysis that included 19 studies, representing 2617 
children from 13 countries, found a prevalence of PDR of 
42.7% in children exposed to ART as treatment for prevention 
of mother-to-child transmission (PMTCT) and 12.7% among 
children not exposed to PMTCT treatment. The prevalence of 
TDR in children not exposed rose from 0% in 2004 to 26.8% in 
2013. NNRTI mutations were found in 32.4% of PMTCT treat-
ment–exposed and in 9.7% of PMTCT treatment–unexposed 
children [24]. Representative data on PDR prevalences are lim-
ited in LMIC, and thus prevalences are likely underestimated.
Factors Associated With Transmission
In Switzerland and the United Kingdom, the major source of 
TDR in men who have sex with men are ART-naïve, HIV-1–
infected individuals [18, 25]. This unexpected finding is due 
to some DRMs with low fitness cost; fitness cost is defined 
as reduced ability of a virus to replicate in the absence of the 
drug. For example, both the DRM L90M, conferring resistance 
to PIs, and the DRM K103N, conferring resistance to NNRTIs, 
have low fitness costs and persist for prolonged periods after 
transmission; they are prevalent in this population [20, 26]. 
Generally, drug-resistant viruses will be gradually replaced by 
fitter viruses in the absence of drug pressure; the rate of replace-
ment depends on the degree of the fitness cost. The sources of 
most transmissions are individuals with acute or recent infec-
tions [27–29]. Recommendations to treat all HIV-1–infected 
individuals, including patients diagnosed early after infection, 
have been inadequately implemented to optimally reduce new 
transmissions [2, 30–35].
Transmission of Minority Variants Harboring Drug-resistant Mutations
Recommendations are given in Appendix Box 2. In 70% to 90% 
of acute HIV-1 infections, single-virus variants are detected. 
However, in 10% to 30%, minority variants are transmitted, 
often at very low frequencies [36–38]. Minority variants har-
boring DRMs have been identified in drug-naive and primary 
infection populations [39–42].
Minority variants harboring DRMs have not been shown to 
negatively affect treatment responses in acutely-infected patients 
[41]; however, in some studies they modestly reduced treatment 
success in chronically-infected drug-naive patients receiving 
first-generation NNRTI (efavirenz or nevirapine)-based treat-
ment [39, 42, 43]. More information on minority variants and 
the relevance of cut-offs to detect different frequencies of vari-
ants harboring DRMs is available in the Supplementary Data.
EMERGENCE OF RESISTANCE WITH LOW-LEVEL 
VIREMIA
Recommendations are given in Appendix Box 3.  Suppression 
of HIV ribonucleic acid (RNA) below limits of quantification 
is the objective of ART [44]. Detectable viremia during ART 
between the limits of the assay quantification (20 to 50 copies/
mL) and 1000 copies/mL is generally referred to as a low-level 
viremia (LLV). An LLV that is transient and only observed in a 
single measurement followed by subsequent undetectable viral 
load is termed a viral blip. A detectable viremia below the limit 
of quantification is referred to as a residual viremia or very LLV. 
The source and clinical relevance of very LLV and viral blips are 
unknown. LLV and blips may reflect technical variability or real 
biologic processes. A  proposed mechanism is the release of a 
virus from activated, latently-infected cells that, in the presence 
of ART, does not result in active rounds of virus replication. 
Low levels of ongoing virus replication due to poor adherence 
or insufficient drug penetration in certain tissues and anatomi-
cal compartments may also occur [45–50].
Drug resistance can emerge in patients with an HIV-1 RNA 
below 1000 copies/mL. Studies have utilized different thresh-
olds for LLV and different criteria for resistance; however, each 
confirmed that drug resistance can emerge at low levels of HIV 
replication, in the range of 50 to 200 copies/mL, with increased 
risk at higher levels in the presence of the selective pressure of 
ART [51–53].
Although resistance assay kits are only approved by the Food 
and Drug Administration for HIV RNA levels above 1000 cop-
ies/mL, resistance testing is feasible at lower ranges of viremia 
[44, 51, 53–55]. During polymerase chain reaction amplifica-
tion, more plasma can be used to increase the amount of HIV 
RNA extracted. The Supplementary Data summarizes existing 
data on the relevance of LLV and blips in treated individuals in 
more detail.
EFFECT OF SUBTYPE ON HIV-1 DRUG RESISTANCE
Recommendations are given in Appendix Box 4. HIV-1 group 
M viruses have evolved into numerous subtypes and circulat-
ing recombinant forms, differing from each other by approxi-
mately 12% in HIV-1 pol. Subtype B viruses account for about 
10% overall, but have been disproportionately studied, as they 
are the predominant subtype in North America and Europe. As 
ART has expanded globally, the effect of subtype on HIV-1 drug 
resistance has received increasing attention.
Virtually all amino acid differences between subtypes are 
polymorphisms: variants that occur commonly in the absence 
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of therapy and have little, if any, phenotypic or clinical effect 
on antiretroviral drugs (ARVs). Thus, most studies suggest 
that individual ARVs and standard ART regimens are similarly 
active, regardless of subtype [56–63]. Increased risk of virologic 
failure has been associated with particular subtypes, but most 
studies are confounded by geographic location, treatment facil-
ities, and clinical, social, and economic statuses that could affect 
outcome differences among individuals infected with different 
subtypes [64–67].
HIV-2 infects more than 1 million persons, most of whom 
reside in or have emigrated from West Africa [68]. It differs 
from HIV-1 by more than 50% of its genome. HIV-2 is intrinsi-
cally resistant to NNRTIs and is variably susceptible to PIs [69, 
70]. The potential impact of different subtypes on ART out-
comes is discussed in the Supplementary Data.
METHODS FOR HIV-1 RESISTANCE TESTING
Recommendations are given in Appendix Box 5.
Resistance Test Options
In most situations, genotypic testing for resistance is the test of 
choice because it is faster, less expensive, and sufficient to pre-
dict drug susceptibility. Phenotypic testing is more expensive, 
technically demanding, and requires a highly-specialized labo-
ratory infrastructure, but is recommended in certain situations. 
Methodologic aspects and challenges of resistance testing are 
described in the Supplementary Data.
The bulk of evidence associating resistance with clinical 
outcomes has been generated with sequencing of plasma HIV 
RNA. For individuals with LLV (ie, <200 copies/mL), sequenc-
ing of peripheral blood mononuclear cell (PBMC) DNA is 
technically feasible and more likely to provide an HIV geno-
type than plasma. However, PBMCs contain HIV DNA that 
has been archived throughout the patient’s infection, and may 
be discordant with plasma testing. Clinicians should judge 
results from PBMC testing with caution [71, 72]. More detailed 
discussion on proviral DNA sequencing is provided in the 
Supplementary Data.
Recommended Genomic Regions for Sequencing
To determine what new regimen to use for patients in whom 
ART is failing, the protease and the first half of the reverse tran-
scriptase (up to at least nucleotide 215) should be sequenced. 
If an InSTI-containing treatment has failed, integrase should 
be sequenced. Although of interest for better understanding of 
patterns at time of failure, baseline InSTI resistance testing is 
currently not cost-effective, as transmitted InSTI resistance is 
infrequent [73]. Baseline InSTI resistance testing should be con-
sidered, however, in select patients with evidence of TDR, such 
as those with nRTI- or multi-class resistances. In such patients, 
the risk of also having transmitted InSTI resistance is likely to 
be higher than in patients without TDR, and the consequences 
of virologic failure on an InSTI-containing initial regimen may 
be more severe.
Sequencing of other regions (C-terminus of reverse tran-
scriptase, group-specific antigen) or even a near-full length of 
HIV-1 might be useful in research settings [74]. Sequencing 
of the third variable loop (V3) of the envelope glycoprotein, 
gp120, can determine whether a virus is R5 tropic, and thus 
might respond to inclusion of a chemokine receptor 5 (CCR5) 
antagonist in ART. Genotypic tropism testing performance 
might be comparable to phenotypic tropism assays, particu-
larly when NGS is used [75–78]. However, testing for genotypic 
tropism from the PBMC compartment is less accurate than 
plasma testing [75]. A more detailed discussion of entry inhib-
itor resistance and novel drug formulations is available in the 
Supplementary Data.
Genotypic Resistance Test Interpretation
Genotypic test results require an interpretation, because there 
are many DRMs that often arise in complex patterns and 
cause varying levels of reduced drug susceptibilities [79, 80]. 
Genotypic test interpretation systems are either rule-based 
or machine-learning systems. Rule-based systems require a 
knowledge base and a set of derived rules. The knowledge base 
usually comprises studies of whether a drug selects a DRM in 
vitro or in patients, whether a DRM reduces drug susceptibility 
in site-directed mutants or clinical isolates, and whether a DRM 
is associated with reduced virologic response to a regimen con-
taining a specific ARV. Virologic response studies have usually 
been performed in the context of clinical trials [81]. Such stud-
ies have assessed the effect of nRTI-associated DRMs on viro-
logic responses to regimens containing abacavir or tenofovir 
disoproxil fumarate [82, 83]; PI-associated DRMs on responses 
to regimens containing lopinavir/ritonavir and darunavir/
ritonavir [84, 85]; NNRTI-associated DRMs on responses to 
regimens containing etravirine [86]; and InSTI-associated 
DRMs on responses to regimens containing dolutegravir [87].
Rule-based systems are more commonly used for interpretation, 
because they consider diverse forms of data and incorporate expert 
opinions [80, 88–90]. These systems are reproducible, transparent, 
and educational, but subjective. Well-described rule-based systems 
include those from the French National Agency for Research on AIDS 
and Viral Hepatitis, Rega, HIV Genotypic Resistance-Algorithm 
Deutschland, and the Stanford HIV Drug Resistance Database 
[80, 91, 92]. Although these systems may produce somewhat dif-
ferent estimates of drug resistance for the same drug, their predic-
tive ability generally has been similar [88, 89, 93]. An online system 
for interpreting HIV-2 sequences has also been developed [94].
Machine-learning systems use datasets containing 
large amounts of data; for example, correlating DRMs in a 
sequence with reduced susceptibility [95–97] or with viro-
logic response to a new treatment regimen [98, 99]. With 
sufficiently large numbers of such correlations, these systems 
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can use genotypic data to predict fold-reductions in suscepti-
bility [95, 96] or the likelihood of virologic suppression with 
a new regimen [97–99].
Interpretation of Phenotypic Resistance Tests
Phenotypic test results require interpretation, because the clin-
ical significance of fold-change reductions in susceptibility 
differs among drugs [98, 100]. Interpretation of these results 
usually requires studies that indicate cutoff values for each drug: 
the fold-reduction in drug susceptibility that exceeds the upper-
most values for wild-type viruses (biologic cutoff) [100]; the 
lowest fold-reduction in susceptibility that indicates reduced 
likelihood of responding to therapy with a drug (lower clini-
cal cutoff); and the lowest fold-reduction in susceptibility that 
indicates a drug will likely be completely inactive (upper clinical 
cutoff). Clinical cutoff values for an ARV are assay-dependent, 
and therefore need to be established for each phenotypic assay 
used in a clinical setting [98, 101].
Limitations of Drug Resistance Interpretation Systems
Genotypic and phenotypic test interpretations cannot pro-
vide specific treatment recommendations, because they do 
not integrate all data required for therapy selection, such as 
treatment history, previous resistance test results, minority 
variants harboring DRM archived in the latent reservoirs, 
plasma HIV-1 RNA level, CD4+ cell count, pharmacologic 
interactions, hepatic and renal status, or the likelihood of 
adherence. Interpretation systems vary in how they account 
for differences in potencies of different ARVs, and do not 
incorporate fundamental principles of how specific regimens 
should be constructed. Therefore, clinicians must either have a 
sound understanding of the principles of therapy to optimally 
use results of drug resistance tests or have access to expertise 
[33, 35]. An extended discussion on interpretation systems is 
available in the Supplementary Data.
CLINICAL APPLICATIONS AND RECOMMENDATIONS
Table 4 summarizes in whom and when genotypic resistance 
testing should be performed. With the recent recommen-
dations to initiate therapy with an InSTI [33], the current 
likelihood of a compromising DRM is low. Regardless, even 
if treatment is initiated quickly, adjustments can be made 
within days if test results so indicate. The HIV-1 RNA thresh-
old of 200 copies/mL is a technical limit; that is, the mini-
mum copy number at which the likelihood of obtaining a test 
result is above 70% [53, 55, 102]. HIV genotyping below 200 
copies/mL may produce clinically meaningful data, but the 
chance of obtaining an interpretable genotype may be too low 
for routine clinical use [53, 55, 102]. Access to drug resistance 
testing may be limited by economic constraints or local tech-
nical capacity.
USE OF GENETIC SEQUENCES FOR OTHER 
PURPOSES
With routine use of resistance testing for clinical purposes in the 
late 1990s [103], it became possible to establish large sequence 
databases [20, 104]. Linking sequences to clinical and epidemi-
ologic data provides a public health infrastructure to monitor 
transmission of drug resistance and the risk conferred by the 
emergence of resistance on therapy. These approaches have also 
defined and validated clinical interpretations of drug resistance, 
such as those described earlier.
Large HIV genetic databases have also facilitated the appli-
cation of increasingly sophisticated phylogenetic-based analy-
ses to assess dynamics of virus spread, taking advantage of the 
inherent variation between sampled viral sequences [105]. This 
approach has uncovered key characteristics of the epidemic, 
particularly where the density of sampling (eg, the proportion 
of infected individuals represented by viral sequence) has been 
high. Use of large-scale viral sequences for purposes other than 
resistance testing is described in the Supplementary Data.
SUMMARY AND FUTURE DIRECTIONS
Despite the unprecedented global rollout and success of ART, 
drug resistance continues to emerge with treatment failure, 
and TDR persists. Divergent patterns of resistance between 
resource-rich and -limited settings have evolved. In the former, 
resistance testing, viral load monitoring, and access to care and 
to ART have resulted in a continuing decrease of acquired drug 
resistance and stable rates of TDR. In contrast, in LMIC, lim-
ited availability of drugs and inadequate monitoring of and act-
ing on viral load and drug resistance has contributed to a steep 
increase in drug resistance. New strategies, such as starting with 
regimens with greater potency and genetic barriers (eg, with 
InSTIs), providing increased options for second- and third-line 
regimens, implementing viral load testing to identify virologic 
failures early, and raising capacities for resistance testing at 
baseline and after treatment failure are prerequisites to secure 
long-term global success of ART [106].
Since the last report [8], recommendations to initiate ART 
have fundamentally changed; all individuals with HIV infec-
tions should be treated as early as possible after infection, 
regardless of CD4+ count [2, 33, 35, 107–111]. Concerns that 
large-scale earlier treatment initiation would give rise to more 
resistance has not been confirmed in resource-rich settings; in 
fact, resistance emergence decreases with earlier treatment ini-
tiation [1, 112, 113].
This report is primarily written for settings that have access to 
resistance testing for HIV patient management, whereas most 
people with HIV live in LMIC, where most HIV drug resis-
tance testing is applied to epidemiologic monitoring. Available 
data on prevalence and TDR or PDR in LMIC are limited and 
delayed, thus often underestimating those numbers.
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In conclusion, testing for HIV drug resistance, and the appre-
ciation of its role, is crucial to the prevention and management 
of failure of ART.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
Notes
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lyzed, and interpreted the data; and prepared, reviewed, and approved the 
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Table 4. Recommendations for Resistance Testing in Clinical Practice: Who and When to Test
Recommendations When to Test
Gene to be Sequenced
Strength/ 
Evidence CommentsProtease
Reverse 
Transcriptasea Integrase
HIV resistance testing is 
recommended for all individuals 
with HIV infection:
•  who are newly diagnosed and 
presumably ART-naïve;
As soon as an individual 
is diagnosed with HIV-1 
infection.
In any case, before ART is 
started.
Yes Yes (Yes)b AIIa To detect transmitted RAM. Early 
testing increases the chances of 
detecting TDR before mutations 
are potentially replaced by wild-
type virus (particularly relevant for 
high–fitness cost mutations, eg, 
M184V, K65R, T215Y, and others). 
Many resistance mutations can 
still be detected even years 
after infection; in particular, 
low–fitness cost mutations (eg, 
K103N, L90M, etc).
InSTI TDR is currently rare.
•  who are on antiretroviral 
treatment and have plasma 
HIV RNA that is rising to above 
200 copies/mL by confirmed 
measurements after they have 
been suppressed to below 50 
copies/mL;
Preferably while on failing 
ART.
Yes Yes Yes AIIa To detect acquired drug resistance 
in patients who initially 
responded to ART and, later on, 
failed.
InSTI RAM should be tested in all 
treatment failures.
•  who have not achieved full virus 
suppression after initiating ART;
≥6 months after ART 
initiation.
Yes Yes Yes AIIa To detect acquired drug resistance 
in patients who did not achieve 
successful viral suppression to 
antiretroviral treatment.
InSTI RAM should be tested in all 
treatment failures.
•  who have interrupted ART 
containing an NNRTI with a long 
half-life (eg, efavirenz); or
As soon as virus rebounds 
above 500 HIV-RNA 
copies/ 
mL, respectively, before 
re-initiation of ART.
Yes Yes Yes AIIa Treatment interruption of such 
regimens can lead to virtual 
monotherapy with rapid 
emergence of resistance.
•  who have a significant increase 
in viral load in a drug-naive 
individual not on treatment.c
After confirmation of 
increase in plasma 
viremia.
Yes Yes (Yes)b AIII Superinfection with drug-resistant 
virus may occur
(consider also tropism testing, 
because a switch from CCR5- to 
CXCR4 tropic virus may have 
occurred).
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; InSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; RAM, resis-
tance-associated mutation; RNA, ribonucleic acid; TDR, transmitted drug resistance.
aSequencing of first half of the reverse transcriptase up to at least nucleotide 215 is sufficient.
bCurrently, evidence of InSTI TDR is rare. Thus “Yes” in brackets (YES) means that InSTI testing should be considered if certain circumstances are given (see comments).
cIncrease of plasma viremia of >0.5 log10 within approximately 3–6 months that is confirmed by a second HIV-1 RNA measurement.
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Box 1. Recommendations for Prevalence of Transmitted or Pretreatment Drug Resistance in Resource-rich and -limited 
Settings (As Available Resources Allow)
• Resistance testing in drug-naive individuals is recommended at the time of diagnosis to detect potential transmitted drug resis-
tance (TDR; evidence rating AIIa).
• TDR and pretreatment drug resistance should be monitored on a country level, accounting for different transmission groups 
(evidence rating AIIa).
• Resistance testing is recommended for perinatally-infected children, particularly those whose mothers received prevention of 
mother-to-child transmission treatment (evidence rating AIIa).
Box 2. Recommendations for Transmission of Minority Variants Harboring Drug-resistant Mutations 
• Drug resistance testing to detect minority variants is not currently recommended outside of research settings, but may be con-
sidered for nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs; evidence rating AIIa).
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Box 3. Recommendations for detection of Resistance With Low-level Viremia
• Samples with a blip exceeding 200 human immunodeficiency virus (HIV)-1 ribonucleic acid (RNA) copies/mL should be con-
sidered for resistance testing, if available (evidence rating CIII).
• Resistance testing is recommended in patients experiencing low-level viremia above 200 copies/mL (evidence rating AIIa) 
viremia.
• To avoid biases during polymerase chain reaction amplification, more plasma can be used to increase the amount of HIV RNA 
extracted (evidence rating BIII).
Box 4. Recommendations for Effect of Subtype on HIV-1 Drug Resistance
• HIV-1 subtype need not be a consideration regarding HIV drug resistance in selecting antiretroviral therapy (ART) regimens 
with nucleoside analogue reverse transcriptase inhibitors (nRTIs), NNRTIs, protease inhibitors (PIs), and integrase strand 
transfer inhibitors (InSTIs; evidence rating AIII).
• For HIV-2, NNRTIs should be avoided regardless of resistance testing, whereas PIs should be used only under the supervision 
of a physician experienced at using this drug class for treating HIV-2 (evidence rating AIIa).
Box 5. Recommendations for Methods for HIV-1 Resistance Testing
• As a first choice, genotypic resistance testing is recommended (evidence rating AIIa).
• Phenotypic resistance testing is recommended, in certain situations:
1. to evaluate HIV susceptibility to new and investigational drugs when drug-resistant mutation patterns have not been fully 
established (evidence rating AIIa);
2. when genotypic test results are too complex to interpret (evidence rating CIII); or
3. when ART options are highly limited and, as a result, salvage ART must rely on residual susceptibilities to different drugs 
that are difficult to predict from genotypic data (evidence rating CIII).
• The recommended compartment for drug resistance testing is plasma (evidence rating AII).
• Inclusion of the protease and first half of the reverse transcriptase (up to at least nucleotide 215) is recommended for all geno-
typic testing (evidence rating BIII).
• Routine InSTI resistance testing in drug-naive individuals is currently not recommended (BIII).
• Baseline InSTI resistance testing is recommended in select patients with evidence of TDR, such as those with nRTI- or multi-
class resistance (evidence rating AIII).
• Monitoring of TDR/pretreatment drug resistance to InSTI in selected sites in resource-rich settings and low- and middle-in-
come countries is recommended (evidence rating AIII).
• Sequencing of other regions (C-terminus of reverse transcriptase, gag) or even a near full-length of HIV-1 is not recommended 
for routine clinical management (evidence rating AIIa).
• Genotypic tropism testing is recommended if a CCR5 antagonist is considered for treatment (evidence rating BIIa).
• Peripheral blood mononuclear cell genotypic resistance testing is recommended in patients with low-level viremia or in patients 
who are virologically suppressed (evidence rating AIII).
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